...
首页> 外文期刊>Cancer gene therapy >Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells
【24h】

Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells

机译:腺病毒介导的针对survivin的siRNA转移增强人非小细胞肺癌细胞的放射敏感性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Expression of survivin has been reported to be correlated with shorter survival in patients with non-small cell lung cancer (NSCLC), and overexpression of survivin may lead to radioresistance in various human cancers. In this study, we inhibited survivin expression by using an adenoviral vector (AdsiSurvivin)-mediated RNA interference to elucidate the combined effect of survivin-targeting gene therapy and radiotherapy on the NSCLC cells. Our data showed that AdsiSurvivin exerted survivin gene silencing, induced apoptosis, and significantly attenuated the growth potential in NSCLC cells within 72?h after infection. The combined treatment modalities with AdsiSurvivin infection and radiation were significantly more potent on cell-growth inhibition than monotherapy. In H1650, H460, A549, and H1975 human NSCLC cells, the survival ratios of AdsiSurvivin-treated groups at multiplicity of infection of 25 and 50 were significantly lower than those of control groups at varying radiation dose (0–8?Gy; three-way analysis of variance, P<0.05). The cytotoxicity of combined AdsiSurvivin infection and irradiation increased in a dose-dependent manner in both the virus and the irradiation treatment. Knockdown of the survivin gene expression seems to be a promising treatment strategy for NSCLC. Our data warrant the need for further effort to develop survivin-targeted radiosensitizer for lung cancer treatment.
机译:据报道,survivin的表达与非小细胞肺癌(NSCLC)患者的生存期较短有关,survivin的过度表达可能导致多种人类癌症的放射抗性。在这项研究中,我们通过使用腺病毒载体(AdsiSurvivin)介导的RNA干扰来阐明survivin靶向基因治疗和放疗对NSCLC细胞的联合作用,从而抑制了survivin的表达。我们的数据表明,AdsiSurvivin在感染后72小时内发挥survivin基因沉默的作用,诱导细胞凋亡,并显着减弱NSCLC细胞的生长潜能。与单一疗法相比,AdsiSurvivin感染和放射的联合治疗方式对细胞生长的抑制作用明显更强。在H1650,H460,A549和H1975人非小细胞肺癌细胞中,AdsiSurvivin治疗组在25和50的感染复数下的存活率显着低于对照组(在不同辐射剂量下(0-8?Gy;三方差分析,P <0.05)。在病毒和放射治疗中,AdsiSurvivin联合感染和放射的细胞毒性均呈剂量依赖性增加。降低survivin基因表达似乎是NSCLC的一种有前途的治疗策略。我们的数据表明需要进一步努力开发靶向survivin的放射增敏剂以治疗肺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号